nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CCR5—Chemokine receptors bind chemokines—CXCL2—esophageal cancer	0.0125	0.0437	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—B2M—esophageal cancer	0.0117	0.0408	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—DOCK2—esophageal cancer	0.00731	0.0255	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—NOS2—esophageal cancer	0.00584	0.0204	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—ELMO1—esophageal cancer	0.00566	0.0198	CbGpPWpGaD
Maraviroc—CYP3A4—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00553	0.0193	CbGpPWpGaD
Maraviroc—CCR5—digestive system—esophageal cancer	0.00531	0.399	CbGeAlD
Maraviroc—CCR5—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00486	0.017	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CXCL2—esophageal cancer	0.0047	0.0164	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—GNG7—esophageal cancer	0.0045	0.0157	CbGpPWpGaD
Maraviroc—CCR5—lung—esophageal cancer	0.00443	0.333	CbGeAlD
Maraviroc—CCR5—Peptide ligand-binding receptors—ANXA1—esophageal cancer	0.00437	0.0153	CbGpPWpGaD
Maraviroc—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00437	0.0153	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—SST—esophageal cancer	0.00425	0.0149	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—B2M—esophageal cancer	0.0042	0.0147	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—GHRL—esophageal cancer	0.00414	0.0145	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CXCL2—esophageal cancer	0.00397	0.0139	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—PSME1—esophageal cancer	0.00396	0.0139	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—PSME2—esophageal cancer	0.00396	0.0139	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.00384	0.0134	CbGpPWpGaD
Maraviroc—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00383	0.0134	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—ANXA1—esophageal cancer	0.00369	0.0129	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—SST—esophageal cancer	0.00359	0.0125	CbGpPWpGaD
Maraviroc—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.00353	0.0123	CbGpPWpGaD
Maraviroc—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00339	0.0119	CbGpPWpGaD
Maraviroc—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.00324	0.0113	CbGpPWpGaD
Maraviroc—Hepatotoxicity—Capecitabine—esophageal cancer	0.00319	0.00456	CcSEcCtD
Maraviroc—Otitis media—Capecitabine—esophageal cancer	0.00317	0.00452	CcSEcCtD
Maraviroc—Coagulopathy—Capecitabine—esophageal cancer	0.00317	0.00452	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00315	0.011	CbGpPWpGaD
Maraviroc—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00307	0.00438	CcSEcCtD
Maraviroc—CCR5—lymph node—esophageal cancer	0.00303	0.228	CbGeAlD
Maraviroc—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00302	0.0106	CbGpPWpGaD
Maraviroc—Polyp—Methotrexate—esophageal cancer	0.00302	0.00431	CcSEcCtD
Maraviroc—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00293	0.0102	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00293	0.0102	CbGpPWpGaD
Maraviroc—Folliculitis—Methotrexate—esophageal cancer	0.00292	0.00417	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00285	0.00997	CbGpPWpGaD
Maraviroc—Proteinuria—Capecitabine—esophageal cancer	0.0028	0.004	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00278	0.00971	CbGpPWpGaD
Maraviroc—Protein urine present—Capecitabine—esophageal cancer	0.00277	0.00395	CcSEcCtD
Maraviroc—Polyuria—Cisplatin—esophageal cancer	0.00276	0.00395	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00275	0.0096	CbGpPWpGaD
Maraviroc—Cyst—Methotrexate—esophageal cancer	0.00274	0.00392	CcSEcCtD
Maraviroc—Rectal haemorrhage—Capecitabine—esophageal cancer	0.00273	0.0039	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—GNG7—esophageal cancer	0.00273	0.00952	CbGpPWpGaD
Maraviroc—Bone marrow depression—Methotrexate—esophageal cancer	0.00272	0.00388	CcSEcCtD
Maraviroc—Deafness—Cisplatin—esophageal cancer	0.00271	0.00387	CcSEcCtD
Maraviroc—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.00271	0.00387	CcSEcCtD
Maraviroc—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.0027	0.00943	CbGpPWpGaD
Maraviroc—Haemolytic anaemia—Cisplatin—esophageal cancer	0.00269	0.00384	CcSEcCtD
Maraviroc—Herpes simplex—Capecitabine—esophageal cancer	0.00267	0.00382	CcSEcCtD
Maraviroc—Nasal congestion—Cisplatin—esophageal cancer	0.00266	0.0038	CcSEcCtD
Maraviroc—Renal failure acute—Cisplatin—esophageal cancer	0.00263	0.00375	CcSEcCtD
Maraviroc—Ulcer—Capecitabine—esophageal cancer	0.00261	0.00372	CcSEcCtD
Maraviroc—Cataract—Capecitabine—esophageal cancer	0.00259	0.0037	CcSEcCtD
Maraviroc—Amnesia—Cisplatin—esophageal cancer	0.00258	0.00369	CcSEcCtD
Maraviroc—Inflammation—Capecitabine—esophageal cancer	0.00254	0.00363	CcSEcCtD
Maraviroc—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00254	0.00886	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—ADCYAP1—esophageal cancer	0.0025	0.00872	CbGpPWpGaD
Maraviroc—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00248	0.00354	CcSEcCtD
Maraviroc—CCR5—Disease—SLC52A3—esophageal cancer	0.00248	0.00865	CbGpPWpGaD
Maraviroc—Herpes zoster—Methotrexate—esophageal cancer	0.00244	0.00348	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—CXCL2—esophageal cancer	0.0024	0.00839	CbGpPWpGaD
Maraviroc—Influenza like illness—Capecitabine—esophageal cancer	0.00239	0.00342	CcSEcCtD
Maraviroc—Hepatotoxicity—Methotrexate—esophageal cancer	0.00238	0.00339	CcSEcCtD
Maraviroc—Colitis—Capecitabine—esophageal cancer	0.00237	0.00338	CcSEcCtD
Maraviroc—CCR5—Disease—KMT2D—esophageal cancer	0.00236	0.00825	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GDI2—esophageal cancer	0.00229	0.00799	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—ANXA1—esophageal cancer	0.00223	0.0078	CbGpPWpGaD
Maraviroc—Urine output increased—Capecitabine—esophageal cancer	0.00223	0.00318	CcSEcCtD
Maraviroc—Neoplasm—Capecitabine—esophageal cancer	0.00223	0.00318	CcSEcCtD
Maraviroc—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00222	0.00316	CcSEcCtD
Maraviroc—Breast disorder—Cisplatin—esophageal cancer	0.00219	0.00313	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00219	0.00312	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—SST—esophageal cancer	0.00217	0.00759	CbGpPWpGaD
Maraviroc—Nasopharyngitis—Cisplatin—esophageal cancer	0.00217	0.0031	CcSEcCtD
Maraviroc—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00212	0.00742	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—GHRL—esophageal cancer	0.00212	0.0074	CbGpPWpGaD
Maraviroc—Proteinuria—Methotrexate—esophageal cancer	0.00209	0.00298	CcSEcCtD
Maraviroc—Sleep disorder—Capecitabine—esophageal cancer	0.00207	0.00295	CcSEcCtD
Maraviroc—Protein urine present—Methotrexate—esophageal cancer	0.00206	0.00294	CcSEcCtD
Maraviroc—Diabetes mellitus—Capecitabine—esophageal cancer	0.00206	0.00294	CcSEcCtD
Maraviroc—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00206	0.00294	CcSEcCtD
Maraviroc—Pancreatitis—Cisplatin—esophageal cancer	0.00206	0.00294	CcSEcCtD
Maraviroc—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00204	0.00713	CbGpPWpGaD
Maraviroc—Polyuria—Capecitabine—esophageal cancer	0.00204	0.00291	CcSEcCtD
Maraviroc—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.00202	0.00288	CcSEcCtD
Maraviroc—Vascular purpura—Capecitabine—esophageal cancer	0.002	0.00286	CcSEcCtD
Maraviroc—Deafness—Capecitabine—esophageal cancer	0.002	0.00286	CcSEcCtD
Maraviroc—Pancytopenia—Cisplatin—esophageal cancer	0.00199	0.00284	CcSEcCtD
Maraviroc—Oliguria—Methotrexate—esophageal cancer	0.00199	0.00284	CcSEcCtD
Maraviroc—Herpes simplex—Methotrexate—esophageal cancer	0.00199	0.00284	CcSEcCtD
Maraviroc—Hepatic failure—Capecitabine—esophageal cancer	0.00199	0.00284	CcSEcCtD
Maraviroc—Haemolytic anaemia—Capecitabine—esophageal cancer	0.00198	0.00283	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00195	0.00681	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00195	0.00681	CbGpPWpGaD
Maraviroc—Ulcer—Methotrexate—esophageal cancer	0.00194	0.00277	CcSEcCtD
Maraviroc—Renal failure acute—Capecitabine—esophageal cancer	0.00194	0.00277	CcSEcCtD
Maraviroc—Amnesia—Capecitabine—esophageal cancer	0.0019	0.00272	CcSEcCtD
Maraviroc—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.0019	0.00271	CcSEcCtD
Maraviroc—Inflammation—Methotrexate—esophageal cancer	0.00189	0.0027	CcSEcCtD
Maraviroc—Vasculitis—Methotrexate—esophageal cancer	0.00188	0.00268	CcSEcCtD
Maraviroc—Respiratory failure—Methotrexate—esophageal cancer	0.00187	0.00267	CcSEcCtD
Maraviroc—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00186	0.0065	CbGpPWpGaD
Maraviroc—Purpura—Capecitabine—esophageal cancer	0.00186	0.00265	CcSEcCtD
Maraviroc—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00184	0.00263	CcSEcCtD
Maraviroc—Renal failure—Cisplatin—esophageal cancer	0.00184	0.00262	CcSEcCtD
Maraviroc—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00183	0.00262	CcSEcCtD
Maraviroc—Myocardial infarction—Cisplatin—esophageal cancer	0.00183	0.00262	CcSEcCtD
Maraviroc—CCR5—Disease—FKBP1A—esophageal cancer	0.00183	0.0064	CbGpPWpGaD
Maraviroc—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00183	0.00261	CcSEcCtD
Maraviroc—Stomatitis—Cisplatin—esophageal cancer	0.00182	0.0026	CcSEcCtD
Maraviroc—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00182	0.00637	CbGpPWpGaD
Maraviroc—Conjunctivitis—Cisplatin—esophageal cancer	0.00182	0.0026	CcSEcCtD
Maraviroc—CCR5—Disease—DOCK2—esophageal cancer	0.00179	0.00625	CbGpPWpGaD
Maraviroc—CCR5—Disease—WIF1—esophageal cancer	0.00179	0.00625	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AKAP13—esophageal cancer	0.00177	0.00619	CbGpPWpGaD
Maraviroc—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00177	0.00253	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00174	0.00607	CbGpPWpGaD
Maraviroc—Urine output increased—Methotrexate—esophageal cancer	0.00166	0.00237	CcSEcCtD
Maraviroc—Neoplasm—Methotrexate—esophageal cancer	0.00166	0.00237	CcSEcCtD
Maraviroc—Urinary tract disorder—Cisplatin—esophageal cancer	0.00166	0.00237	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—KMT2D—esophageal cancer	0.00165	0.00578	CbGpPWpGaD
Maraviroc—CCR5—Disease—CSNK1A1—esophageal cancer	0.00165	0.00577	CbGpPWpGaD
Maraviroc—Connective tissue disorder—Cisplatin—esophageal cancer	0.00165	0.00236	CcSEcCtD
Maraviroc—Urethral disorder—Cisplatin—esophageal cancer	0.00165	0.00235	CcSEcCtD
Maraviroc—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00165	0.00575	CbGpPWpGaD
Maraviroc—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00163	0.00233	CcSEcCtD
Maraviroc—Abdominal pain upper—Capecitabine—esophageal cancer	0.00163	0.00233	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—PDE4D—esophageal cancer	0.00162	0.00566	CbGpPWpGaD
Maraviroc—Breast disorder—Capecitabine—esophageal cancer	0.00162	0.00231	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00161	0.0023	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00161	0.0023	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—AKAP13—esophageal cancer	0.00161	0.00562	CbGpPWpGaD
Maraviroc—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.0016	0.00561	CbGpPWpGaD
Maraviroc—Nasopharyngitis—Capecitabine—esophageal cancer	0.0016	0.00228	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00158	0.00225	CcSEcCtD
Maraviroc—Eye disorder—Cisplatin—esophageal cancer	0.00157	0.00224	CcSEcCtD
Maraviroc—Lymphadenopathy—Methotrexate—esophageal cancer	0.00156	0.00223	CcSEcCtD
Maraviroc—Cardiac disorder—Cisplatin—esophageal cancer	0.00156	0.00222	CcSEcCtD
Maraviroc—Abdominal distension—Capecitabine—esophageal cancer	0.00156	0.00222	CcSEcCtD
Maraviroc—Influenza—Capecitabine—esophageal cancer	0.00155	0.00221	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—GNG7—esophageal cancer	0.00154	0.00538	CbGpPWpGaD
Maraviroc—Diabetes mellitus—Methotrexate—esophageal cancer	0.00153	0.00219	CcSEcCtD
Maraviroc—Bronchospasm—Capecitabine—esophageal cancer	0.00152	0.00217	CcSEcCtD
Maraviroc—Polyuria—Methotrexate—esophageal cancer	0.00152	0.00217	CcSEcCtD
Maraviroc—Mediastinal disorder—Cisplatin—esophageal cancer	0.00151	0.00216	CcSEcCtD
Maraviroc—Angina pectoris—Capecitabine—esophageal cancer	0.00151	0.00215	CcSEcCtD
Maraviroc—Bronchitis—Capecitabine—esophageal cancer	0.00149	0.00212	CcSEcCtD
Maraviroc—Alopecia—Cisplatin—esophageal cancer	0.00148	0.00212	CcSEcCtD
Maraviroc—Hepatic failure—Methotrexate—esophageal cancer	0.00148	0.00212	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—ADCYAP1—esophageal cancer	0.00147	0.00515	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PDE4D—esophageal cancer	0.00147	0.00514	CbGpPWpGaD
Maraviroc—Pancytopenia—Capecitabine—esophageal cancer	0.00147	0.0021	CcSEcCtD
Maraviroc—Erythema—Cisplatin—esophageal cancer	0.00146	0.00209	CcSEcCtD
Maraviroc—Malnutrition—Cisplatin—esophageal cancer	0.00146	0.00209	CcSEcCtD
Maraviroc—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00146	0.00509	CbGpPWpGaD
Maraviroc—Neutropenia—Capecitabine—esophageal cancer	0.00145	0.00206	CcSEcCtD
Maraviroc—Renal failure acute—Methotrexate—esophageal cancer	0.00144	0.00206	CcSEcCtD
Maraviroc—Flatulence—Cisplatin—esophageal cancer	0.00144	0.00206	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00144	0.00205	CcSEcCtD
Maraviroc—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00141	0.00201	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—GNG7—esophageal cancer	0.0014	0.00489	CbGpPWpGaD
Maraviroc—CCR5—Disease—ELMO1—esophageal cancer	0.00139	0.00485	CbGpPWpGaD
Maraviroc—Pneumonia—Capecitabine—esophageal cancer	0.00139	0.00198	CcSEcCtD
Maraviroc—Infestation—Capecitabine—esophageal cancer	0.00138	0.00197	CcSEcCtD
Maraviroc—Infestation NOS—Capecitabine—esophageal cancer	0.00138	0.00197	CcSEcCtD
Maraviroc—Depression—Capecitabine—esophageal cancer	0.00137	0.00196	CcSEcCtD
Maraviroc—Tremor—Cisplatin—esophageal cancer	0.00137	0.00195	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00137	0.00195	CcSEcCtD
Maraviroc—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00136	0.00194	CcSEcCtD
Maraviroc—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00136	0.00194	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—CXCL2—esophageal cancer	0.00136	0.00474	CbGpPWpGaD
Maraviroc—CCR5—Disease—TPI1—esophageal cancer	0.00136	0.00474	CbGpPWpGaD
Maraviroc—CCR5—Disease—GSTO1—esophageal cancer	0.00136	0.00474	CbGpPWpGaD
Maraviroc—Renal failure—Capecitabine—esophageal cancer	0.00136	0.00193	CcSEcCtD
Maraviroc—Myocardial infarction—Capecitabine—esophageal cancer	0.00135	0.00193	CcSEcCtD
Maraviroc—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00135	0.00193	CcSEcCtD
Maraviroc—Anaemia—Cisplatin—esophageal cancer	0.00135	0.00193	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—WWOX—esophageal cancer	0.00135	0.00471	CbGpPWpGaD
Maraviroc—Jaundice—Capecitabine—esophageal cancer	0.00134	0.00192	CcSEcCtD
Maraviroc—Stomatitis—Capecitabine—esophageal cancer	0.00134	0.00192	CcSEcCtD
Maraviroc—Conjunctivitis—Capecitabine—esophageal cancer	0.00134	0.00191	CcSEcCtD
Maraviroc—Leukopenia—Cisplatin—esophageal cancer	0.00131	0.00187	CcSEcCtD
Maraviroc—Hepatobiliary disease—Capecitabine—esophageal cancer	0.0013	0.00186	CcSEcCtD
Maraviroc—CCR5—Disease—ALDOB—esophageal cancer	0.0013	0.00454	CbGpPWpGaD
Maraviroc—Agranulocytosis—Capecitabine—esophageal cancer	0.00129	0.00184	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—FKBP1A—esophageal cancer	0.00128	0.00448	CbGpPWpGaD
Maraviroc—Convulsion—Cisplatin—esophageal cancer	0.00127	0.00181	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—ANXA1—esophageal cancer	0.00126	0.00441	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—WIF1—esophageal cancer	0.00125	0.00438	CbGpPWpGaD
Maraviroc—CCR5—Disease—HIST1H2BM—esophageal cancer	0.00125	0.00437	CbGpPWpGaD
Maraviroc—CCR5—Disease—GAPDH—esophageal cancer	0.00125	0.00437	CbGpPWpGaD
Maraviroc—Myalgia—Cisplatin—esophageal cancer	0.00124	0.00178	CcSEcCtD
Maraviroc—Rhinitis—Capecitabine—esophageal cancer	0.00124	0.00177	CcSEcCtD
Maraviroc—Anxiety—Cisplatin—esophageal cancer	0.00124	0.00177	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00124	0.00432	CbGpPWpGaD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00124	0.00176	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CXCL2—esophageal cancer	0.00123	0.00431	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00123	0.0043	CbGpPWpGaD
Maraviroc—Discomfort—Cisplatin—esophageal cancer	0.00123	0.00176	CcSEcCtD
Maraviroc—Pharyngitis—Capecitabine—esophageal cancer	0.00123	0.00175	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—SST—esophageal cancer	0.00123	0.00429	CbGpPWpGaD
Maraviroc—Urinary tract disorder—Capecitabine—esophageal cancer	0.00122	0.00174	CcSEcCtD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00122	0.00426	CbGpPWpGaD
Maraviroc—Connective tissue disorder—Capecitabine—esophageal cancer	0.00122	0.00174	CcSEcCtD
Maraviroc—Urethral disorder—Capecitabine—esophageal cancer	0.00121	0.00173	CcSEcCtD
Maraviroc—Breast disorder—Methotrexate—esophageal cancer	0.0012	0.00172	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.0012	0.00171	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—GHRL—esophageal cancer	0.0012	0.00418	CbGpPWpGaD
Maraviroc—Oedema—Cisplatin—esophageal cancer	0.00119	0.0017	CcSEcCtD
Maraviroc—Infection—Cisplatin—esophageal cancer	0.00119	0.00169	CcSEcCtD
Maraviroc—Erythema multiforme—Capecitabine—esophageal cancer	0.00117	0.00167	CcSEcCtD
Maraviroc—Nervous system disorder—Cisplatin—esophageal cancer	0.00117	0.00167	CcSEcCtD
Maraviroc—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.00116	0.00405	CbGpPWpGaD
Maraviroc—Skin disorder—Cisplatin—esophageal cancer	0.00116	0.00165	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CSNK1A1—esophageal cancer	0.00116	0.00404	CbGpPWpGaD
Maraviroc—Eye disorder—Capecitabine—esophageal cancer	0.00116	0.00165	CcSEcCtD
Maraviroc—Cardiac disorder—Capecitabine—esophageal cancer	0.00115	0.00164	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—ANXA1—esophageal cancer	0.00115	0.004	CbGpPWpGaD
Maraviroc—Eosinophilia—Methotrexate—esophageal cancer	0.00114	0.00163	CcSEcCtD
Maraviroc—Anorexia—Cisplatin—esophageal cancer	0.00114	0.00162	CcSEcCtD
Maraviroc—Pancreatitis—Methotrexate—esophageal cancer	0.00113	0.00161	CcSEcCtD
Maraviroc—Angiopathy—Capecitabine—esophageal cancer	0.00112	0.0016	CcSEcCtD
Maraviroc—Mediastinal disorder—Capecitabine—esophageal cancer	0.00112	0.00159	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—SST—esophageal cancer	0.00111	0.00389	CbGpPWpGaD
Maraviroc—CCR5—Disease—XIAP—esophageal cancer	0.00111	0.00386	CbGpPWpGaD
Maraviroc—Alopecia—Capecitabine—esophageal cancer	0.00109	0.00156	CcSEcCtD
Maraviroc—Pancytopenia—Methotrexate—esophageal cancer	0.00109	0.00156	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00109	0.00155	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—GHRL—esophageal cancer	0.00109	0.0038	CbGpPWpGaD
Maraviroc—Mental disorder—Capecitabine—esophageal cancer	0.00108	0.00155	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PFN1—esophageal cancer	0.00108	0.00378	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00108	0.00377	CbGpPWpGaD
Maraviroc—Erythema—Capecitabine—esophageal cancer	0.00108	0.00154	CcSEcCtD
Maraviroc—Malnutrition—Capecitabine—esophageal cancer	0.00108	0.00154	CcSEcCtD
Maraviroc—Neutropenia—Methotrexate—esophageal cancer	0.00108	0.00154	CcSEcCtD
Maraviroc—Paraesthesia—Cisplatin—esophageal cancer	0.00107	0.00153	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00107	0.00153	CcSEcCtD
Maraviroc—Flatulence—Capecitabine—esophageal cancer	0.00106	0.00152	CcSEcCtD
Maraviroc—Decreased appetite—Cisplatin—esophageal cancer	0.00104	0.00148	CcSEcCtD
Maraviroc—Pneumonia—Methotrexate—esophageal cancer	0.00103	0.00147	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00103	0.00147	CcSEcCtD
Maraviroc—CCR5—Disease—B2M—esophageal cancer	0.00103	0.00359	CbGpPWpGaD
Maraviroc—Infestation—Methotrexate—esophageal cancer	0.00103	0.00147	CcSEcCtD
Maraviroc—Infestation NOS—Methotrexate—esophageal cancer	0.00103	0.00147	CcSEcCtD
Maraviroc—Depression—Methotrexate—esophageal cancer	0.00102	0.00146	CcSEcCtD
Maraviroc—Pain—Cisplatin—esophageal cancer	0.00102	0.00146	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00102	0.00145	CcSEcCtD
Maraviroc—Tremor—Capecitabine—esophageal cancer	0.00101	0.00144	CcSEcCtD
Maraviroc—Renal failure—Methotrexate—esophageal cancer	0.00101	0.00144	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.001	0.0035	CbGpPWpGaD
Maraviroc—Stomatitis—Methotrexate—esophageal cancer	0.001	0.00143	CcSEcCtD
Maraviroc—Conjunctivitis—Methotrexate—esophageal cancer	0.000998	0.00142	CcSEcCtD
Maraviroc—Anaemia—Capecitabine—esophageal cancer	0.000996	0.00142	CcSEcCtD
Maraviroc—CCR5—Disease—ENO1—esophageal cancer	0.000986	0.00344	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ELMO1—esophageal cancer	0.000972	0.0034	CbGpPWpGaD
Maraviroc—CCR5—Disease—PSME2—esophageal cancer	0.000971	0.00339	CbGpPWpGaD
Maraviroc—CCR5—Disease—PSME1—esophageal cancer	0.000971	0.00339	CbGpPWpGaD
Maraviroc—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000971	0.00139	CcSEcCtD
Maraviroc—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000967	0.00338	CbGpPWpGaD
Maraviroc—Syncope—Capecitabine—esophageal cancer	0.000966	0.00138	CcSEcCtD
Maraviroc—Leukopenia—Capecitabine—esophageal cancer	0.000964	0.00138	CcSEcCtD
Maraviroc—Agranulocytosis—Methotrexate—esophageal cancer	0.000958	0.00137	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—AKAP13—esophageal cancer	0.00095	0.00332	CbGpPWpGaD
Maraviroc—Loss of consciousness—Capecitabine—esophageal cancer	0.000947	0.00135	CcSEcCtD
Maraviroc—Body temperature increased—Cisplatin—esophageal cancer	0.000943	0.00135	CcSEcCtD
Maraviroc—Cough—Capecitabine—esophageal cancer	0.00094	0.00134	CcSEcCtD
Maraviroc—CCR5—Disease—CALR—esophageal cancer	0.000932	0.00326	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000921	0.00322	CbGpPWpGaD
Maraviroc—Myalgia—Capecitabine—esophageal cancer	0.000917	0.00131	CcSEcCtD
Maraviroc—Pharyngitis—Methotrexate—esophageal cancer	0.000914	0.00131	CcSEcCtD
Maraviroc—Anxiety—Capecitabine—esophageal cancer	0.000914	0.0013	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000911	0.0013	CcSEcCtD
Maraviroc—Urinary tract disorder—Methotrexate—esophageal cancer	0.00091	0.0013	CcSEcCtD
Maraviroc—Discomfort—Capecitabine—esophageal cancer	0.000906	0.00129	CcSEcCtD
Maraviroc—Urethral disorder—Methotrexate—esophageal cancer	0.000903	0.00129	CcSEcCtD
Maraviroc—CCR5—Disease—FBXW7—esophageal cancer	0.000901	0.00315	CbGpPWpGaD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000881	0.00308	CbGpPWpGaD
Maraviroc—Oedema—Capecitabine—esophageal cancer	0.000879	0.00126	CcSEcCtD
Maraviroc—Hypersensitivity—Cisplatin—esophageal cancer	0.000879	0.00125	CcSEcCtD
Maraviroc—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000879	0.00307	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000877	0.00306	CbGpPWpGaD
Maraviroc—Infection—Capecitabine—esophageal cancer	0.000874	0.00125	CcSEcCtD
Maraviroc—Erythema multiforme—Methotrexate—esophageal cancer	0.000871	0.00124	CcSEcCtD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00087	0.00304	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PDE4D—esophageal cancer	0.000869	0.00304	CbGpPWpGaD
Maraviroc—Shock—Capecitabine—esophageal cancer	0.000865	0.00123	CcSEcCtD
Maraviroc—Nervous system disorder—Capecitabine—esophageal cancer	0.000862	0.00123	CcSEcCtD
Maraviroc—Eye disorder—Methotrexate—esophageal cancer	0.000861	0.00123	CcSEcCtD
Maraviroc—Asthenia—Cisplatin—esophageal cancer	0.000856	0.00122	CcSEcCtD
Maraviroc—Cardiac disorder—Methotrexate—esophageal cancer	0.000855	0.00122	CcSEcCtD
Maraviroc—Skin disorder—Capecitabine—esophageal cancer	0.000854	0.00122	CcSEcCtD
Maraviroc—Anorexia—Capecitabine—esophageal cancer	0.000838	0.0012	CcSEcCtD
Maraviroc—Angiopathy—Methotrexate—esophageal cancer	0.000836	0.00119	CcSEcCtD
Maraviroc—Mediastinal disorder—Methotrexate—esophageal cancer	0.00083	0.00119	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—GNG7—esophageal cancer	0.000826	0.00289	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000826	0.00289	CbGpPWpGaD
Maraviroc—Diarrhoea—Cisplatin—esophageal cancer	0.000816	0.00117	CcSEcCtD
Maraviroc—Alopecia—Methotrexate—esophageal cancer	0.000814	0.00116	CcSEcCtD
Maraviroc—Mental disorder—Methotrexate—esophageal cancer	0.000807	0.00115	CcSEcCtD
Maraviroc—Erythema—Methotrexate—esophageal cancer	0.000802	0.00114	CcSEcCtD
Maraviroc—Malnutrition—Methotrexate—esophageal cancer	0.000802	0.00114	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000801	0.00114	CcSEcCtD
Maraviroc—Insomnia—Capecitabine—esophageal cancer	0.000795	0.00114	CcSEcCtD
Maraviroc—Paraesthesia—Capecitabine—esophageal cancer	0.00079	0.00113	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—XIAP—esophageal cancer	0.000774	0.00271	CbGpPWpGaD
Maraviroc—Decreased appetite—Capecitabine—esophageal cancer	0.000764	0.00109	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00076	0.00266	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000759	0.00108	CcSEcCtD
Maraviroc—Vomiting—Cisplatin—esophageal cancer	0.000758	0.00108	CcSEcCtD
Maraviroc—Fatigue—Capecitabine—esophageal cancer	0.000758	0.00108	CcSEcCtD
Maraviroc—Rash—Cisplatin—esophageal cancer	0.000752	0.00107	CcSEcCtD
Maraviroc—Pain—Capecitabine—esophageal cancer	0.000752	0.00107	CcSEcCtD
Maraviroc—Constipation—Capecitabine—esophageal cancer	0.000752	0.00107	CcSEcCtD
Maraviroc—Dermatitis—Cisplatin—esophageal cancer	0.000751	0.00107	CcSEcCtD
Maraviroc—Anaemia—Methotrexate—esophageal cancer	0.000741	0.00106	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CTNNA1—esophageal cancer	0.000732	0.00256	CbGpPWpGaD
Maraviroc—CCR5—Disease—TGFBR2—esophageal cancer	0.000729	0.00255	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCL2—esophageal cancer	0.000728	0.00254	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000719	0.00103	CcSEcCtD
Maraviroc—Leukopenia—Methotrexate—esophageal cancer	0.000718	0.00102	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000714	0.0025	CbGpPWpGaD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00071	0.00248	CbGpPWpGaD
Maraviroc—Nausea—Cisplatin—esophageal cancer	0.000709	0.00101	CcSEcCtD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000701	0.00245	CbGpPWpGaD
Maraviroc—Cough—Methotrexate—esophageal cancer	0.0007	0.000999	CcSEcCtD
Maraviroc—Abdominal pain—Capecitabine—esophageal cancer	0.000695	0.000992	CcSEcCtD
Maraviroc—Body temperature increased—Capecitabine—esophageal cancer	0.000695	0.000992	CcSEcCtD
Maraviroc—Convulsion—Methotrexate—esophageal cancer	0.000695	0.000992	CcSEcCtD
Maraviroc—CCR5—Disease—SMAD4—esophageal cancer	0.00069	0.00241	CbGpPWpGaD
Maraviroc—Myalgia—Methotrexate—esophageal cancer	0.000683	0.000975	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PSME1—esophageal cancer	0.00068	0.00238	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PSME2—esophageal cancer	0.00068	0.00238	CbGpPWpGaD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000678	0.000968	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000677	0.00237	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ANXA1—esophageal cancer	0.000677	0.00237	CbGpPWpGaD
Maraviroc—Discomfort—Methotrexate—esophageal cancer	0.000675	0.000963	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000668	0.00233	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000659	0.0023	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SST—esophageal cancer	0.000658	0.0023	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000653	0.00228	CbGpPWpGaD
Maraviroc—Infection—Methotrexate—esophageal cancer	0.00065	0.000928	CcSEcCtD
Maraviroc—Hypersensitivity—Capecitabine—esophageal cancer	0.000648	0.000925	CcSEcCtD
Maraviroc—Nervous system disorder—Methotrexate—esophageal cancer	0.000642	0.000916	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—NOTCH3—esophageal cancer	0.000642	0.00224	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GHRL—esophageal cancer	0.000642	0.00224	CbGpPWpGaD
Maraviroc—Skin disorder—Methotrexate—esophageal cancer	0.000636	0.000908	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—FBXW7—esophageal cancer	0.000631	0.00221	CbGpPWpGaD
Maraviroc—Asthenia—Capecitabine—esophageal cancer	0.000631	0.000901	CcSEcCtD
Maraviroc—Anorexia—Methotrexate—esophageal cancer	0.000624	0.000891	CcSEcCtD
Maraviroc—Pruritus—Capecitabine—esophageal cancer	0.000622	0.000888	CcSEcCtD
Maraviroc—Diarrhoea—Capecitabine—esophageal cancer	0.000602	0.000859	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000596	0.000851	CcSEcCtD
Maraviroc—Insomnia—Methotrexate—esophageal cancer	0.000592	0.000845	CcSEcCtD
Maraviroc—Paraesthesia—Methotrexate—esophageal cancer	0.000588	0.000839	CcSEcCtD
Maraviroc—Dizziness—Capecitabine—esophageal cancer	0.000581	0.00083	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000576	0.00201	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOTCH2—esophageal cancer	0.000576	0.00201	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000573	0.002	CbGpPWpGaD
Maraviroc—Decreased appetite—Methotrexate—esophageal cancer	0.000569	0.000812	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000565	0.000807	CcSEcCtD
Maraviroc—CCR5—Disease—HIF1A—esophageal cancer	0.000565	0.00197	CbGpPWpGaD
Maraviroc—Fatigue—Methotrexate—esophageal cancer	0.000564	0.000806	CcSEcCtD
Maraviroc—Pain—Methotrexate—esophageal cancer	0.00056	0.000799	CcSEcCtD
Maraviroc—Vomiting—Capecitabine—esophageal cancer	0.000559	0.000798	CcSEcCtD
Maraviroc—Rash—Capecitabine—esophageal cancer	0.000554	0.000791	CcSEcCtD
Maraviroc—Dermatitis—Capecitabine—esophageal cancer	0.000554	0.000791	CcSEcCtD
Maraviroc—Headache—Capecitabine—esophageal cancer	0.000551	0.000786	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000541	0.00189	CbGpPWpGaD
Maraviroc—CYP3A4—digestive system—esophageal cancer	0.000535	0.0402	CbGeAlD
Maraviroc—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000535	0.000764	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000533	0.00186	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000525	0.00184	CbGpPWpGaD
Maraviroc—Nausea—Capecitabine—esophageal cancer	0.000522	0.000746	CcSEcCtD
Maraviroc—Abdominal pain—Methotrexate—esophageal cancer	0.000517	0.000739	CcSEcCtD
Maraviroc—Body temperature increased—Methotrexate—esophageal cancer	0.000517	0.000739	CcSEcCtD
Maraviroc—CCR5—Disease—NOS2—esophageal cancer	0.000514	0.00179	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TGFBR2—esophageal cancer	0.000511	0.00178	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOTCH1—esophageal cancer	0.000509	0.00178	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000495	0.00173	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000488	0.00171	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SMAD4—esophageal cancer	0.000483	0.00169	CbGpPWpGaD
Maraviroc—Hypersensitivity—Methotrexate—esophageal cancer	0.000482	0.000688	CcSEcCtD
Maraviroc—Asthenia—Methotrexate—esophageal cancer	0.00047	0.00067	CcSEcCtD
Maraviroc—Pruritus—Methotrexate—esophageal cancer	0.000463	0.000661	CcSEcCtD
Maraviroc—CCR5—Disease—CREBBP—esophageal cancer	0.000461	0.00161	CbGpPWpGaD
Maraviroc—Diarrhoea—Methotrexate—esophageal cancer	0.000448	0.000639	CcSEcCtD
Maraviroc—Dizziness—Methotrexate—esophageal cancer	0.000433	0.000618	CcSEcCtD
Maraviroc—Vomiting—Methotrexate—esophageal cancer	0.000416	0.000594	CcSEcCtD
Maraviroc—CCR5—Disease—NOS3—esophageal cancer	0.000413	0.00144	CbGpPWpGaD
Maraviroc—Rash—Methotrexate—esophageal cancer	0.000413	0.000589	CcSEcCtD
Maraviroc—Dermatitis—Methotrexate—esophageal cancer	0.000412	0.000589	CcSEcCtD
Maraviroc—Headache—Methotrexate—esophageal cancer	0.00041	0.000585	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000404	0.00141	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HIF1A—esophageal cancer	0.000395	0.00138	CbGpPWpGaD
Maraviroc—Nausea—Methotrexate—esophageal cancer	0.000389	0.000555	CcSEcCtD
Maraviroc—CCR5—Disease—ERBB2—esophageal cancer	0.000386	0.00135	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000384	0.00134	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000379	0.00133	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KDR—esophageal cancer	0.000378	0.00132	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTGS2—esophageal cancer	0.000378	0.00132	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.00036	0.00126	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOTCH1—esophageal cancer	0.000356	0.00124	CbGpPWpGaD
Maraviroc—CCR5—Disease—CDKN1A—esophageal cancer	0.00033	0.00115	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CREBBP—esophageal cancer	0.000323	0.00113	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—EGFR—esophageal cancer	0.000317	0.00111	CbGpPWpGaD
Maraviroc—CCR5—Disease—EP300—esophageal cancer	0.000314	0.0011	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000306	0.00107	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000303	0.00106	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000302	0.00105	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOS3—esophageal cancer	0.000289	0.00101	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000288	0.001	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000284	0.000991	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CA—esophageal cancer	0.000275	0.000963	CbGpPWpGaD
Maraviroc—CCR5—Disease—MYC—esophageal cancer	0.000274	0.000956	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ERBB2—esophageal cancer	0.000271	0.000945	CbGpPWpGaD
Maraviroc—CCR5—Disease—EGFR—esophageal cancer	0.000268	0.000936	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCND1—esophageal cancer	0.000239	0.000835	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CA—esophageal cancer	0.000232	0.000812	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN1A—esophageal cancer	0.000231	0.000808	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EP300—esophageal cancer	0.00022	0.000769	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MYC—esophageal cancer	0.000192	0.00067	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EGFR—esophageal cancer	0.000187	0.000655	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CA—esophageal cancer	0.000163	0.000569	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TP53—esophageal cancer	0.000157	0.00055	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000155	0.00054	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000155	0.00054	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000131	0.000459	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CA1—esophageal cancer	0.000131	0.000459	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CA2—esophageal cancer	0.00012	0.00042	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.000112	0.00039	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ADH7—esophageal cancer	0.000112	0.00039	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ADH1B—esophageal cancer	9.8e-05	0.000342	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TYMP—esophageal cancer	9.36e-05	0.000327	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP26A1—esophageal cancer	9.11e-05	0.000318	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALOX15—esophageal cancer	8.88e-05	0.00031	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TPI1—esophageal cancer	8.47e-05	0.000296	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTO1—esophageal cancer	8.47e-05	0.000296	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALDOB—esophageal cancer	8.12e-05	0.000284	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GAPDH—esophageal cancer	7.81e-05	0.000273	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CRABP1—esophageal cancer	7.74e-05	0.000271	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GNG7—esophageal cancer	7.37e-05	0.000257	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALDH2—esophageal cancer	6.9e-05	0.000241	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTT1—esophageal cancer	6.57e-05	0.000229	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP2A6—esophageal cancer	6.49e-05	0.000227	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ENO1—esophageal cancer	6.15e-05	0.000215	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS1—esophageal cancer	6.15e-05	0.000215	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PSME1—esophageal cancer	6.06e-05	0.000212	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PSME2—esophageal cancer	6.06e-05	0.000212	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP1B1—esophageal cancer	5.23e-05	0.000183	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.92e-05	0.000172	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HMOX1—esophageal cancer	4.49e-05	0.000157	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCB1—esophageal cancer	4.31e-05	0.000151	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.88e-05	0.000101	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NOS3—esophageal cancer	2.58e-05	9.01e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.36e-05	8.24e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—EP300—esophageal cancer	1.96e-05	6.85e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.45e-05	5.07e-05	CbGpPWpGaD
